Managing individuals with propensity to myeloid malignancies due to germline RUNX1 deficiency

marrow microenvironment. 7 We plan to carry out a second clinical trial using bortezomib for initial induction therapy as well as incorporating it into the conditioning regimen. Based upon the results of these two studies, the regimen with superior phase II results will be compared to a standard melphalan-based SCT in a randomized phase III study, with the goal of determining whether the addition of bortezomib leads to a higher rate of hematologic and clinical responses, and better progression-free and overall survival.